On a year-to-date basis, the stock has outperformed the SOX index by over 5 percentage points. Analysts believe AI server demand will be a key catalyst, potentially lifting the share price above the $190 mark. Insmed (INSM) Rides on FDA Nod for First Bronchiectasis Drug The Zacks Analyst is encouraged by the recent FDA approval of Insmed's Brinsupri' the first treatment for non-CF bronchiectasis. This also marks the launch of the company's second marketed product. Benzinga Edge Rankings: According to Benzinga Edge stock rankings, AMD boasts an exceptional Growth score of 94.28, underscoring its strong market position. The stock price of AMD has been holding above the $185 level, supported by strong institutional buying. Fundamentally, AMD’s GPU lineup for AI computing continues to capture market share from competitors, a trend that could drive earnings surprises this quarter. Traders see $190 as a near-term psychological level.
